Safety

Rapamune (sirolimus)oral solution and tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

November 2015

Summary View

WARNINGS AND PRECAUTIONS

Interstitial Lung Disease/Non-Infectious Pneumonitis
  • In some cases, the ILD was reported with pulmonary hypertension (including pulmonary arterial hypertension [PAH]) as a secondary event.

 

April 2010

Summary View 

WARNINGS AND PRECAUTIONS

Fluid Accumulation and Wound Healing
  • ascites
Assay for Sirolimus Therapeutic Drug Monitoring
  • Currently in clinical practice, sirolimus whole blood concentrations are being measured by various chromatographic and immunoassay methodologies. Patient sample concentration values from different assays may not be interchangeable

ADVERSE REACTIONS

  • Cardiovascular: and fluid accumulation
  • Digestive System: Ascites

 

Page Last Updated: 12/11/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English